Basic Research

HOME > R&D Achievement > Basic Research > Article
 
DATE : 21-06-10 11:59
Poly-L-lactide Polymer-Based Triple Drug-Eluting Stent with Abciximab, Alpha-Lipoic Acid and Sirolimus in Porcine Coronary Restenosis Model
 WRITER : stent
HIT : 1,394  
   B102.+Poly-L-lactide+Polymer-Based+Triple+Drug-Eluting+Stent+with+Abciximab,+Alpha-Lipoic+Acid+and+Sirolimus+in+Porcine+Coronary+Restenosis+Model.pdf (1.7M) [0] DATE : 2021-06-10 11:59:56
Jun-Kyu Park, Myung Ho Jeong , Sung Soo Kim†,2 Hyun Kuk Kim2 Jae-Woon Nah3 Han Byul Kim4 In Ho Bae4,5,6 Dae Sung Park4,5,6,7 Jae Won Shim4,5,6 Min Young Lee8 Joong Sun Kim9 Bon-Sang Koo10 Kang-Jin Jeong10 Yeong Bae Jin10 Sun-Uk Kim10 Sang-Rae Lee10 Joo-Young Na11 Doo Sun

Poly-L-lactide Polymer-Based Triple Drug-Eluting Stent with Abciximab, Alpha-Lipoic Acid and Sirolimus in Porcine Coronary Restenosis Model

This study evaluated the effect of a novel triple drug-eluting stent containing antithrombotic abciximab, antioxidative alpha-lipoic acid (ALA), and antiproliferative sirolimus in a porcine model. The coronary arteries of pigs were randomized into three groups: triple drug-eluting stent (TES; n=10), sirolimus-eluting stent (SES; n=10), and bare metal stent (BMS; n=10). At 28 days after stent implantation, a histopathologic analysis was performed. There were no significant differences in the injury score. There were significant differences in the neointimal area (2.3±0.6 mm2 in TES vs. 2.5±0.88 mm2 in SES vs. 3.3±0.58 mm2 in BMS, p<0.0001), percent area of stenosis (37.1±9.26% in TES vs. 46.1±15.9% in SES vs. 66.2±10.12% in BMS, p<0.0001),
 inflammation score (1.0 [range, 0.0-1.0] in TES vs. 1.5 [range, 1.0-2.0] in SES vs. 1.0 [range, 1.0-2.0] in BMS, p<0.05), and fibrin score (2.0 [range, 1.0-2.0] in TES vs. 2.0 [range, 1.0-2.5] in SES vs. 0.0 [range, 0.0-1.0] in BMS, p<0.0001) among the three groups.
 The occlusion rates using micro-computed tomography showed similar restenosis rates based on histologic analysis (35.4±8.39% in TES vs. 43.4±10.12% in SES vs. 71.4±4.38% in BMS, p<0.0001). TES demonstrated an inhibitory effect on the smooth muscle cells compared to the other stents. It also suppressed inflammation in the stented lesion compared to SES as evidenced by the inflammation score